Loading clinical trials...
Loading clinical trials...
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Conditions
Interventions
Pegilodecakin
Nivolumab
Locations
35
United States
Arizona Oncology Associates, P.C.
Tempe, Arizona, United States
Beverly Hills Cancer Center
Beverly Hills, California, United States
Glendale Adventist Medical Center
Los Angeles, California, United States
Redwood Regional Oncology Center
Santa Rosa, California, United States
The Oncology Institute of Hope and Innovation
Whittier, California, United States
Rocky Mountain Cancer Center
Lone Tree, Colorado, United States
Start Date
March 22, 2018
Primary Completion Date
August 28, 2019
Completion Date
March 3, 2020
Last Updated
September 11, 2020
NCT05671510
NCT03340506
NCT07485114
NCT06066138
NCT05098132
NCT04977453
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions